The efficacy of ginseng supplement in the prevention of cardiac toxicity induced by anthracyclines
Phase 3
Recruiting
- Conditions
- cardiac disease.Cardiomyopathy due to drug and external agentI42.7
- Registration Number
- IRCT20141227020441N7
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
The ages of 18 to 65 years
Patients with non-metastatic breast cancer
Receiving the first course of anthracycline based chemotherapy
Exclusion Criteria
History of therapy with anthracyclines
Metastatic or recurrent breast cancer
History of solid tumors and receiving systemic therapy
LVEF below 50%
History of chronic diseases ( DM, cardiac disease. renal failure)
Pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiotoxicity will be assessed based on LVEF and Trop I. Timepoint: will be evaluated baseline and after completion of chemotherapy cycles (3 monthes). Method of measurement: LVEF and Trop I will be assessed with echocardiography and blood samples respectively.
- Secondary Outcome Measures
Name Time Method